Our findings suggest that pharmacological activation and enhancement of the LXA4/ALX pathway is a promising therapeutic strategy in ischemic stroke to combat neuroinflammation, reduce neuronal death, and improve neurological recovery although further characterization of optimal activation and enhancement of the LXA4 pathway is necessary to determine its full potential in resolving neuroinflammation after ischemic stroke. The gene discussed is FPR2; the disease is ischemic stroke.